<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02854488</url>
  </required_header>
  <id_info>
    <org_study_id>CA184-487</org_study_id>
    <nct_id>NCT02854488</nct_id>
  </id_info>
  <brief_title>Yervoy Pregnancy Surveillance Study</brief_title>
  <official_title>A Global Enhanced Pharmacovigilance Pregnancy Surveillance Study of Pregnant Women Exposed to Yervoy With 5 -Year Pediatric Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      The study is a global safety surveillance study of pregnancy outcomes in women who were
      exposed to ipilimumab during pregnancy and pediatric outcomes up to 5 years of age
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2016</start_date>
  <completion_date type="Anticipated">August 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of structural birth defects in infants born to mothers exposed to Yervoy while pregnant</measure>
    <time_frame>Birth up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of chromosomal birth defects in infants born to mothers exposed to Yervoy while pregnant</measure>
    <time_frame>Birth up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Delays in developmental milestones</measure>
    <time_frame>Birth up to 5 Years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Signs of Immune or Endocrine Dysfunction</measure>
    <time_frame>Birth up to 5 Years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Signs of Autoimmune Disorders</measure>
    <time_frame>Birth up to 5 Years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Signs of Serious Infections and Malignancy</measure>
    <time_frame>Birth up to 5 Years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Pregnancy Outcomes</measure>
    <time_frame>Time of Conception up to Birth</time_frame>
    <description>Elective or spontaneous abortion, fetal death/stillbirth, pre-term delivery, ectopic or molar pregnancy</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Women Exposed to Yervoy (ipilimumab) During Pregnancy</arm_group_label>
    <description>Women Exposed to Yervoy (ipilimumab) During Pregnancy and the Children from These Pregnancies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yervoy</intervention_name>
    <arm_group_label>Women Exposed to Yervoy (ipilimumab) During Pregnancy</arm_group_label>
    <other_name>ipilimumab</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary Care Clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented exposure to Yervoy while pregnant or within 90 days of discontinuing
             treatment

        Exclusion Criteria:

          -  Women whose ipilimumab exposure is outside the window of pregnancy exposure

          -  Pregnancies for which there is only paternal exposure to Yervoy

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>{ Recruiting sites have contact information. Please contact the sites { directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UBC</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505-8065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Miller, Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2016</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

